Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 3/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26754222 | 0.81 | GRIK1 (0.34) | GRIK1GRIK2ALDH1A1MAPTPTGS1 | |
| SCHEMBL13898634 | 0.81 | GRIK1 (0.52) | GRIK1GRIK2PTGS1SLC7A5 | |
| SCHEMBL17718260 | 0.81 | GRIK1 (0.52) | GRIK1GRIK2PTGS1SLC7A5 | |
| SCHEMBL16017804 | 0.81 | GRIK1 (0.52) | GRIK1GRIK2PTGS1SLC7A5 | |
| SCHEMBL16017787 | 0.77 | GRIK1 (0.32) | GRIK1SLC7A5 | |
| SCHEMBL16185835 | 0.77 | GRIK1 (0.37) | GRIK1GRIK2 | |
| SCHEMBL16841491 | 0.77 | GRIK1 (0.37) | GRIK1GRIK2 | |
| SCHEMBL20830102 | 0.75 | GABRP (0.37) | GRIK1ALDH1A1MAPTPTGS1SLC7A5 | |
| SCHEMBL13019133 | 0.74 | — | — | |
| SCHEMBL14117404 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9737523-B2 | Anti-fibrogenic compounds, methods and uses thereof | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-08-22 | — | — | US | disclosed |
| US-20160120857-A1 | Anti-Fibrogenic Compounds, Methods and Uses Thereof | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120857-A1 | Anti-Fibrogenic Compounds, Methods and Uses Thereof | KYNU, AADAT, KMO | GRIK1 309/4885GRIK2 396/4885ALDH1A1 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.